UTI Guides FY2027 Revenue to $925-945M as Net Income Falls to $0-5M on Growth Spend
UTI is trading near its 52-week low of $18.02 (3.8% above the low).
Summary
UTI reported FY2026 revenue of $897.0 million (+7.4%) and Q4 adjusted EBITDA of $42.5 million (+15.5%), but guided FY2027 net income down to $0-5 million as it funds up to 12 new campuses and roughly 45 new programs toward $1.2 billion of revenue by FY2029.
Key Events · Earnings and Guidance · UTI
-
Q4 Revenue Grows 6.0% to $235.9M
Fourth-quarter revenue rose to $235.9 million from $222.4 million, with adjusted EBITDA up 15.5% to $42.5 million. Full-year revenue was $897.0 million, up 7.4%.
-
FY2027 Net Income Guided to $0-5M
FY2027 guidance calls for revenue of $925-945 million but net income of only $0-5 million (EPS $0.00-0.09) and adjusted EBITDA of $100-106 million, as roughly $35 million of EBITDA is consumed by growth investments.
-
Multi-Year Targets: $1.2B Revenue by FY2029
Management projects revenue above $1 billion and adjusted EBITDA approaching $150 million in FY2028, then revenue above $1.2 billion and adjusted EBITDA approaching $220 million in FY2029.
-
Up to 12 New Campuses Planned
The plan covers up to 12 new campuses and approximately 45 new programs from FY2027 through FY2029, adding capacity for more than 10,000 students, all subject to regulatory approval.
Analysis · UTI · Trade & Services
Full-year revenue rose 7.4% to $897.0 million and Q4 adjusted EBITDA jumped 15.5% to $42.5 million, but the forward plan is what matters: management is spending heavily on new campuses and programs and told investors FY2027 net income will collapse to $0-5 million from $33.6 million, with adjusted EBITDA flat at $100-106 million. The stock is already near its 52-week low of $18.02, so the market has been pricing in margin pain. The offset is a credible multi-year ramp — revenue above $1 billion and adjusted EBITDA approaching $150 million in FY2028, then above $1.2 billion and approaching $220 million in FY2029. Execution is the risk: 12 new campuses and roughly 45 new programs all need regulatory approval, and FY2026 already produced negative adjusted free cash flow of $(12.6) million on $112.9 million of capex.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UTI was trading at $18.70 on NYSE in the Trade & Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $18.02 to $51.34. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.